Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BetterLife Pharma Inc BETRF


Primary Symbol: C.BETR

Healthcare
BetterLife Pharma Inc. is a biotechnology company. The Company is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001, which is in preclinical and is a non-hallucinogenic and non- controlled lysergic acid diethylamide (LSD) derivative in development and that is unregulated and therefore can be... see more

Recent & Breaking News (CSE:BETR)

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments

GlobeNewswire January 26, 2023

BetterLife Pharma (CSE:BETR) closes private placement

Azuka Onwuka December 7, 2022

BetterLife Announces Closing of Private Placement

GlobeNewswire December 7, 2022

BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, Arizona

GlobeNewswire December 2, 2022

BetterLife (CSE:BETR) files a comprehensive patent for BETR-001 and other LSD derivatives

Brieanna McCutcheon  September 27, 2022

BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives

GlobeNewswire September 27, 2022

BetterLife (CSE:BETR) to submit research publication

Sabrina Cuthbert September 7, 2022

BetterLife and Collaborators to Submit Key Joint Research Publication

GlobeNewswire September 7, 2022

BetterLife (CSE:BETR) drug offers treatment without hallucinogenic side effects

Sabrina Cuthbert August 24, 2022

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

GlobeNewswire August 24, 2022

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

GlobeNewswire July 6, 2022

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference

GlobeNewswire June 23, 2022

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

GlobeNewswire June 21, 2022

BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference

GlobeNewswire April 21, 2022

BetterLife's BETR-001 Demonstrates BETR-001 Anti-depressant Activity in Preclinical Models of Depression

GlobeNewswire April 6, 2022

BetterLife Obtains In Vivo PK Data for BETR-001 Confirming its Bioavailability in Brain

GlobeNewswire March 16, 2022

BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model

GlobeNewswire February 15, 2022

BetterLife Launches New Corporate Website

GlobeNewswire February 10, 2022

BetterLife Receives FDA Response On Its Pre-IND Application For Major Depressive Disorder (MDD) Treatment With BETR-001

GlobeNewswire January 20, 2022

BetterLife (CSE:BETR) advances non-hallucinogenic psychedelic treatment BETR-001

Julia Kennedy  January 18, 2022